Cancer Medicines to Get Cheaper? Government Sets 30% Trade Margin Cap

The Government of India has approved a 30% trade-margin cap on non-scheduled anti-cancer medicines in a move aimed at making cancer treatment more affordable. The measure covers branded and generic medicines, domestically manufactured and imported drugs, and patented and non-patented cancer treatments. The government estimates that the change could reduce the maximum retail prices (MRPs) of certain medicines by up to 70% and save patients approximately ₹2,500 crore annually.

The decision comes amid growing scrutiny of the substantial mark-ups applied to some cancer medicines between manufacturers and patients. An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines covered by the measure. The move expands the government’s efforts to control excessive medicine pricing and reduce out-of-pocket healthcare expenditure.

What Is the Government’s New 30% Trade-Margin Cap?

The new policy limits trade margins on non-scheduled cancer medicines to 30% of their maximum retail price. Trade margins represent the difference between the prices at which medicines move through the supply chain and the amounts charged to consumers.

The government is targeting the mark-ups applied by distributors, wholesalers, retailers and other points in the supply chain rather than imposing a single new ceiling on the prices charged by manufacturers.

According to Business Standard, the government intends to cover 110 non-scheduled cancer drugs, including 35 patented medicines. The final list of eligible medicines and brands is being prepared by the expert committee.

Key Details of the Cancer Drug Pricing Decision

Particular	Details
Trade-margin cap	30%
Target medicines	Non-scheduled anti-cancer drugs
Medicines covered in the reported scope	110
Patented medicines included	35
Potential reduction in selected MRPs	Up to 70%
Estimated annual patient savings	₹2,500 crore
Implementing authorities	Department of Pharmaceuticals and NPPA, with DGHS committee input

Sources: Press Information Bureau and Business Standard.

The expected price reductions will vary by medicine and its existing supply-chain mark-ups. The government has not suggested that every cancer drug will automatically become 70% cheaper.

Why Are Cancer Medicines So Expensive in India?

Cancer treatment can involve repeated chemotherapy sessions, targeted therapies, immunotherapy and other medicines prescribed over extended periods. For some patients, the cost of medicines represents a substantial share of their overall treatment expenditure.

One factor identified by the government is the gap between the price manufacturers charge distributors and the maximum retail price printed on medicines.

According to officials cited by Business Standard, trade mark-ups on certain cancer medicines have ranged from approximately 170% to 700%. Such differences can substantially increase the amount patients pay, particularly when medicines are purchased through retail or hospital pharmacies.

The Supreme Court has also questioned the large differences between the price to retailer and MRP of certain cancer medicines. The issue has brought renewed attention to whether existing regulations adequately protect patients purchasing medicines that can be essential to their treatment.

The new cap aims to address excessive mark-ups while retaining a distribution system through which medicines can reach patients.

Scheduled vs Non-Scheduled Cancer Drugs

Understanding the distinction between scheduled and non-scheduled medicines is important because the new decision focuses on the latter category.

Category	Existing Pricing Framework	Impact of New Decision
Scheduled medicines	Subject to government-regulated ceiling prices under applicable rules	Existing price controls continue
Non-scheduled cancer medicines	Generally outside the same formulation-level ceiling-price mechanism	Trade margins capped at 30% under the approved measure
Branded and generic drugs	Treatment depends on the applicable pricing category and rules	Included if covered by the new framework
Patented and imported drugs	Subject to relevant existing regulations	Included in the reported scope of the new measure

The National Pharmaceutical Pricing Authority (NPPA) regulates medicine prices under the Drugs (Prices Control) Order, 2013. Scheduled formulations are subject to applicable ceiling prices, while non-scheduled formulations are generally subject to a different regulatory framework.

The new decision extends trade-margin regulation to a wider group of non-scheduled cancer medicines. It does not mean that all medicines will be subject to an identical manufacturer selling price.

How Much Could Cancer Patients Save?

The government estimates annual savings of approximately ₹2,500 crore from the measure, with potential MRP reductions of up to 70% for certain medicines. These are official estimates, and the actual savings will depend on the medicines covered, their existing prices and the extent to which the lower prices are passed on to patients.

For patients purchasing expensive medicines repeatedly, even a smaller reduction can make a meaningful difference over a full course of treatment.

For example, consider a medicine with an existing monthly cost of ₹50,000. A hypothetical 30% reduction in the amount paid would lower the cost to ₹35,000, saving ₹15,000 per month.

This example is illustrative only. It is not a forecast for any particular medicine, and the 30% trade-margin cap does not translate into a uniform 30% reduction in every medicine’s final price.

Actual savings will depend on the final regulated price, the medicine’s supply chain and the applicable implementation rules.

Government Has Expanded Cancer Drug Price Controls Before

The latest decision builds on an earlier intervention introduced in 2019.

That year, the government imposed a 30% trade-margin cap on 42 selected non-scheduled cancer medicines. According to the NPPA, the measure reduced the MRPs of 526 brands by an average of around 50% and generated annual savings of approximately ₹984 crore for patients.

The latest decision seeks to extend the approach to a broader group of non-scheduled anti-cancer medicines.

The earlier intervention provides evidence that trade-margin regulation can reduce listed prices for selected products. However, the effects of the expanded framework will depend on the final list of medicines, the way margins are calculated and how effectively the new limits are enforced.

What Role Will the NPPA Play?

The NPPA is responsible for implementing and monitoring pharmaceutical price controls under the relevant regulations.

For the latest measure, the expert committee under the DGHS will identify the medicines to be covered. The Department of Pharmaceuticals and the NPPA will play important roles in translating the decision into an operational pricing framework.

Implementation will require clear rules on which products qualify, how the permitted margin is calculated and how compliance is monitored across different sales channels.

The authorities will also need to address differences between hospital pharmacies, retail outlets and online pharmacies, where the prices paid by patients can vary. The government has identified substantial variations in transaction prices across these channels.

Could the Policy Affect Pharmaceutical Companies?

The decision could affect manufacturers, distributors and retailers that sell the covered medicines.

Companies may need to review their pricing structures and supply-chain arrangements to ensure that the applicable trade margins remain within the permitted limit. Businesses that previously relied on high mark-ups could face pressure to adjust their pricing and distribution strategies.

However, the effect will differ across companies and products. The policy does not automatically establish that every manufacturer must reduce its selling price by the same percentage.

Industry representatives have also raised concerns about the design of a broader trade-margin rationalisation framework. Some smaller pharmaceutical businesses have argued that changes to margins could affect their commercial arrangements and the economics of distributing medicines in less-served markets.

The government’s challenge will be to reduce excessive pricing without undermining the availability and distribution of important cancer medicines.

Will the 30% Cap Extend to Other Medicines?

The government is also examining whether trade-margin rationalisation could eventually be extended beyond cancer drugs to other non-scheduled medicines, medical consumables and devices.

Business Standard reported that the Department of Pharmaceuticals and NPPA have been holding consultations on a broader framework. Products such as intravenous kits and catheters could also be considered in future policy discussions.

However, the cancer-drug decision should be distinguished from any wider proposal. The current measure specifically concerns non-scheduled anti-cancer medicines, while the timing and scope of broader reforms remain separate questions.

The Bigger Picture

The 30% trade-margin cap marks an expansion of India’s efforts to regulate the cost of cancer medicines. By targeting mark-ups across the supply chain, the government is seeking to reduce the gap between medicine acquisition costs and the prices patients ultimately pay.

The policy could provide significant relief to patients who depend on expensive cancer treatments, particularly if the projected price reductions are achieved. Its wider significance will depend on transparent implementation, effective enforcement and the ability to maintain a reliable supply of medicines.

Looking Ahead

The next step is for the expert committee to finalise the list of covered medicines and for the authorities to clarify the implementation requirements. Patients, hospitals, pharmacies and pharmaceutical companies will need to follow the official notifications to understand which products are affected and when revised prices will apply.

For cancer patients and their families, the most important measure of success will be the actual reduction in medicine bills. The government’s projected annual savings of ₹2,500 crore indicate the potential scale of the intervention, but the final impact will become clearer as the new pricing framework is implemented and monitored.